Jones G E, Jones K A, Machell J, Brebner J, Anderson I E, How S
Moredun Research Institute, Edinburgh, UK.
Vaccine. 1995;13(8):715-23. doi: 10.1016/0264-410x(94)00068-x.
Vaccines containing inactivated, semi-purified antigen of ovine abortifacient Chlamydia psittaci were prepared from tissue-culture grown harvests of two strains. These were evaluated for efficacy against experimentally reproduced enzootic abortion of ewes (EAE), the protection index (PI) of each vaccine being calculated from three variables. Trial 1 tested the adjuvants Marcol 52/Arlacel A, ISCOM matrix, Novasomes and Alhydrogel, each administered with a total antigen dose of 4 micrograms chlamydial protein (cp), against challenge with the two homologous vaccine strains. The first three formulations yielded PIs of 39-42%, while that of Alhydrogel was 23%. Marked granuloma and/or abscess formation occurred in the Marcol 52/Arlacel A group but in none of the others, and only this group seroconverted following vaccination. In Trial 2, ISCOM matrix containing 16 micrograms cp per dose was administered once or twice. Two challenges were used, one involving the two vaccine strains and the other these two strains plus five others, but no significant differences were seen between them. The double dose schedule, which was better than the single dose and also several Novasomes formulations tested concurrently, gave PIs of 64 and 77% against the two challenges (combined value 71.5%). Trial 3 studied duration of immunity over two lambing seasons using three different administration schedules of 16 micrograms cp in ISCOM matrix, namely single dose in year 1, single dose in year 2 (Group 1), double dose then booster (Group 2), and double dose without booster (Group 3). PIs against the homologous bivalent challenge were 79-80% for Groups 1 and 3 and 91% for Group 2.(ABSTRACT TRUNCATED AT 250 WORDS)
含有绵羊流产嗜衣原体灭活、半纯化抗原的疫苗，是从两种菌株的组织培养收获物中制备的。对这些疫苗进行了抗实验性诱发母羊地方流行性流产（EAE）的效力评估，每种疫苗的保护指数（PI）由三个变量计算得出。试验1测试了佐剂Marcol 52/Arlacel A、免疫刺激复合物（ISCOM）基质、新型脂质体和氢氧化铝凝胶，每种佐剂均与4微克衣原体蛋白（cp）的总抗原剂量一起给药，以对抗两种同源疫苗株的攻击。前三种制剂的PI为39%-42%，而氢氧化铝凝胶的PI为23%。Marcol 52/Arlacel A组出现了明显的肉芽肿和/或脓肿形成，而其他组均未出现，并且只有该组在接种疫苗后出现了血清转化。在试验2中，每剂含有16微克cp的ISCOM基质给药一次或两次。使用了两次攻击，一次涉及两种疫苗株，另一次涉及这两种菌株加另外五种菌株，但未观察到它们之间有显著差异。双剂量方案优于单剂量方案，也优于同时测试的几种新型脂质体制剂，在两次攻击中的PI分别为64%和77%（合并值71.5%）。试验3使用ISCOM基质中16微克cp的三种不同给药方案，研究了两个产羔季节的免疫持续时间，即第1年单剂量、第2年单剂量（第1组）、双剂量然后加强免疫（第2组）和双剂量不加强免疫（第3组）。第1组和第3组针对同源二价攻击的PI为79%-80%，第2组为91%。（摘要截断于250字）
